Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | USP7 | Q93009 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845373 | 0.92 | TP53 (0.35) | PTK2MAPK14LMNAHPGD | |
| SCHEMBL24173941 | 0.92 | GRM1 (0.39) | GRM5GRM1USP7 | |
| SCHEMBL22845431 | 0.90 | GRM5 (0.38) | GRM5GRM1 | |
| SCHEMBL22845201 | 0.86 | S1PR2 (0.33) | GRM1MAPK14USP7 | |
| SCHEMBL22845502 | 0.86 | GRM1 (0.34) | GRM5GRM1USP7 | |
| SCHEMBL22845357 | 0.85 | PRLHR (0.35) | — | |
| SCHEMBL22845442 | 0.84 | GRM5 (0.34) | GRM5GRM1MAPK14 | |
| SCHEMBL22845531 | 0.84 | MAPK14 (0.35) | GRM5KCNK3MAPK14 | |
| SCHEMBL22845388 | 0.83 | PREP (0.35) | GRM1MAPK14 | |
| SCHEMBL22845318 | 0.83 | PRLHR (0.33) | GRM5GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | GRM5 3636/4885GRM1 4264/4885PTK2 4823/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | GRM5 3636/4885GRM1 4264/4885PTK2 4823/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | GRM5 3636/4885GRM1 4264/4885PTK2 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.